Table 1. Study participant characteristics.

Characteristics	Development Cohort		Validation Cohort
	PTLDs	Recovered	PTLDs	Recovered
N	15	14	10	13
Age (mean years)	59	59	61	52
Female gender–no. (%)	6 (40)	4 (29)	3 (27)	6 (46)
Lyme Disease Presentation*—no. (%)
Single Erythema Migrans	4 (27)	8 (57)	1 (9)	6 (46)
Multiple Erythema Migrans	1 (7)	0	0	3 (23)
Flu-like illness with seroconversion	2 (13)	1 (7)	3 (27)	1 (8)
Acute Neuroborreliosis	4 (27)	2 (14)	0	3 (23)
Carditis	0	1 (7)	0	0
Arthritis	2 (13)	2 (14)	4 (36)	0
Late Neuroborreliosis	2 (13)	0	2 (20)	0
Single or Multiple Erythema Migrans**	9	9	4	10
Previous Antibiotic Treatment***
Number of oral courses—median (range)	2 (0–6)	1 (1)	2 (1–2)	1 (1–3)
Number of IV courses—median (range)	1 (0–4)	0 (0–1)	1 (0–1)	0 (0–1)
Time from Suspected Infection to Therapy
median days (range)	24 (3–840)	16 (1–300)	82 (1–1,825)	10 (1–45)
Current Symptoms—no. (%)
Fatigue	13 (87)	1 (7)	8 (80)	2 (15)
Concentration/memory changes	11 (73)	1 (7)	7 (70)	2 (15)
Arthralgia	5 (33)	5 (35)	8 (80)	4 (30.7)
Myalgia	3 (20)	0	4 (40)	1 (7.6)
Headache	4 (27)	1 (7)	4 (40)	5 (38)
Paresthesias	4 (27)	0	5 (50)	2 (15)
Word finding difficulties	6 (40)	1 (7)	2 (20)	1 (7.6)
Alterations in behavior/mood	5 (33)	0	3 (30)	2 (15)
Sleep disturbance	5 (33)	1 (7)	1 (10)	3 (23)
Stiff neck	3 (20)	1 (7)	2 (20)	1 (7.6)
Dizziness/lightheadedness	1 (7)	0	3 (30)	1 (7.6)
Tinnitus	1 (7)	3 (21)	0	2 (15)
Night sweats	0	0	1 (10)	0

*Main manifestation of Lyme disease.

**Total number of patients who had erythema migrans or multiple erythema migrans as a manifestation of Lyme disease.

***The duration of antibiotic treatment for each course varied between 2 to 4 weeks.

PTLDs: post-treatment Lyme disease symptoms.